Tolera Therapeutics

• Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

  Phase 1/2, Status unknown, 85 people, Jun 30, 2010

Sources: clinicaltrials.gov

• Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS

  Grants or research support, Jun 15, 2021

Sources: pubmed.ncbi.nlm.nih.gov